Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials

about

Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials

Item

http://www.wikidata.org/entity/Q57074340

description

article

@en

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Risk of selected gastrointesti ...... a-analysis of published trials

@en

Risk of selected gastrointestinal toxicities associated with poly

@nl

type

Item

label

Risk of selected gastrointesti ...... a-analysis of published trials

@en

Risk of selected gastrointestinal toxicities associated with poly

@nl

prefLabel

Risk of selected gastrointesti ...... a-analysis of published trials

@en

Risk of selected gastrointestinal toxicities associated with poly

@nl

P1476

Risk of selected gastrointesti ...... a-analysis of published trials

@en

P2093

Guichan Wang

http://www.w3.org/2001/XMLSchema#string

Jun Meng

http://www.w3.org/2001/XMLSchema#string

Yongping Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Operating characteristics of a rank correlation test for publication bias

Cancer statistics, 2014

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Beta blockade during and after myocardial infarction: an overview of the randomized trials.

P304

3013-3019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.2147/DDDT.S164553

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30271116

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

drug discovery

ovarian cancer

P932

6147204

http://www.w3.org/2001/XMLSchema#string